Triple Negative Breast Cancer

P1/2, N=260, Terminated, Amgen | Completed --> Terminated; Sponsor Decision

P1, N=27, Active, not recruiting, Institut Paoli-Calmettes | Recruiting --> Active, not recruiting

In vivo, carvacrol effectively suppressed TNBC vascularization and growth in a mouse dorsal skinfold chamber model and an orthotopic xenograft model. Together, these findings suggest that carvacrol preferentially targets angiogenesis and VM in TNBC by suppressing the TRPM7/Zn2+/mTOR/RTKs axis, highlighting it as a promising therapeutic candidate for TNBC and potentially other tumors resistant to anti-angiogenic therapies, while positioning the TRPM7 channel as a novel anti-vascular target for TNBC treatment.

In this Romanian single-center cohort, pCR was independently predicted by clinical subtype and a limited set of biological variables, in line with contemporary literature. Although baseline patient-reported outcomes did not improve prediction of pathological response, the high prevalence of pre-treatment anxiety and the emergence of clinical depression during NAC argue for systematic psychosocial screening as part of standard neoadjuvant care.

Breast cancer cells (i.e., MCF7 and MDA-MB231) infected with a combination of recombinant HSV-1 viruses that express granulocyte-macrophage colony-stimulating factor (GM-CSF) and metformin exhibit a synergistic effect in promoting the expression of interferon-ϒ (IFN-ϒ) found within peripheral blood mononuclear cells (PBMCs) and exerting apoptotic and cytotoxic effects in the mentioned malignant cells. The online version contains supplementary material available at 10.1007/s12088-025-01523-7.

Adjuvant therapy comprised paclitaxel (175 mg/m²) plus cisplatin (75 mg/m²) every 3 weeks for six cycles, combined with pembrolizumab (200 mg every 3 weeks). To our knowledge, this is one of the first reported cases of pembrolizumab combined with platinum-based chemotherapy in the adjuvant setting for primary triple-negative NEBC. This case provides hypothesis-generating evidence for chemo-immunotherapy in this rare, high-grade histologic subtype.

Toripalimab combined with chemotherapy (Toripa-chemo) showed the greatest OS benefit in the overall population (HR = 0.58, 95% CI: 0.38-0.87). Atezolizumab combined with Entinostat and chemotherapy (Atezo-Entino-chemo) showed a trend toward improved OS (HR = 0.49, 95% CI: 0.22-1.12) and ORR (OR = 5.14, 95% CI: 0.70-37.94)...Toripa-chemo and Pembro-chemo demonstrate a balanced profile of efficacy and safety, suggesting that they may be suitable options for first-line treatment of mTNBC. Among these, Toripa-chemo may be considered a preferred first-line regimen for PD-L1 positive patients. https://www.crd.york.ac.uk/prospero/, identifier ID: CRD420251138714.

Safety and efficacy were consistent with results from IMpassion130, which enrolled a more selected population.

T cell-specific Ramp1 deletion similarly restrained tumor growth, and RAMP1⁺ CD8⁺ T cells in human TNBC displayed an exhaustion-associated phenotype. Together, these findings define a tumor-promoting proNGF-nociceptor-CGRP-RAMP1 axis and identify neuroimmune signaling as a therapeutically actionable vulnerability in TNBC.

Induced electric field therapy enhances anti-tumor immunity and suppresses metastatic progression in TNBC by enhancing T cell activity and remodeling immunosuppressive myeloid environments. These findings support iEFs as a promising non-invasive immunomodulatory strategy for metastatic TNBC.

In this analysis, gBRCAmut carriers treated with KN522 achieved remarkably high pCR rates. The observed 40% hospitalizations, primarily due to NF, highlights the need for supportive care optimization, including G-CSF consideration.

Receptor discordance between primary tumors and nodal metastases is common, with most shifts occurring within the HER2-spectrum. There was a trend toward higher RS and ER or HER2-receptor discordance. HER2 discordance was also associated with larger tumor size and larger size of nodal metastasis. As strategies emerge to target HER2-low cohorts and to include ER-low/HER2-negative disease within treatment regimens for TNBC, it may become important to consider receptor testing of nodal disease in the future.